

Generic Pipeline & Paragraph IV Candidates				
API	Medical Indication	Branded Drug and Sales in 2016*	MAPI Asset	MAPI IP
Glatiramer Acetate	RRMS	Copaxone® (Teva)	API	
Fingolimod HCl Commercial	RRMS	Gilenya (Novartis)	API & FDF	Processes US Granted
Apremilast Commercial	Psoriatic arthritis	Otezla® (Celgene)	API & FDF	Polymorph (PCT)
Darunavir	HIV	Prezista® (J&J)	API & FDF	Processes (US/EP Granted) Polymorph US Granted
Trabectedin	Sarcoma	Yondelis® (J&J)	API	
Buspirone ER	Anti-anxiety agent / Non-sedative / anxiolytic	Actavis Inc; Bristol-Myers	FDF	Provisional on ER
Abiraterone Acetate (Para.IV)	Prostate Cancer	Zytiga® (J&J)	API	Processes US Granted
Perampanel	Epilepsy	Fycompa® (Eisai)	API & FDF	Polymorph US Allowed
Lurasidone HCl	Schizophrenia	Latuda® (DSP)	API	Processes US Granted
Dronedarone HCl	Atrial Fibrillation	Multaq® (Sanofi)	API	
Febuxostat	Chronic Hyperuricemia	Uloric® (Takeda)	API	Processes (PCT) Polymorph (PCT)
Deferasirox	Chronic Iron Overload	Exjade® (Norvatis)	API	Processes & Polymorph US Granted EP Allowed
Indacaterol Maleate	Chronic Obstructive Pulmonary Disease	Onbrez®, Arcapta (Novartis)	API & FDF	
Tapentadol HCl	Acute Pain	Nucynta®, Palexia® (J&J)	API	Processes US Granted
Alogliptin Benzoate	Diabetes	Nesina® (Takeda)	API	Processes US Granted
Selexipag	PAH - Pulmonary Arterial Hypertension	Uptravi® (Nippon Shinyaku)	API & FDF	Polymorph (PCT)
Dapagliflozin	Type 2 Diabetes	Forxiga® (BMS & AstraZeneca)	API & FDF	CO-CRYSTALS US Granted
Partnered	*2015-2016 Sales based on Thomson Reuters' Cortellis platform		API: Active Pharmaceutical Ingredient	FDF: Finished Dosage Form